163 results about "Oxyde nitrique" patented technology

Nitric oxide releasing oxindole prodrugs are described which are useful in methods of treating or preventing pain, inflammation, fever, or gastrointestinal lesions in a patient in need of such treatment, or of modifying an inflammatory disease or condition by favorably affecting the outcome thereof in said patient, wherein there is administered to said patient a therapeutically effective amount of a compound of Formula (I): and pharmaceutically acceptable salts thereof. In preferred embodiments, X is a covalent bond; RA and RB are both hydrogen; n is the integer 4; Y is -O-; Z is -NO2; RC is a member selected from the group consisting essentially of 5-Cl and 5-F; RD is a member selected from the group consisting essentially of 6-Cl and 6-F; and RE is a member selected from the group consisting essentially of benzyl, 2-furyl, 2-thienyl, 5-chloro-2-thienyl and 5-trifluoromethyl-2-thienyl.

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.

The combination of amlodipine and atorvastatin act to synergistically synthesize NO production. Moreover, the addition of a tertiary compound complements this combination of amlodipine and atorvastatin in NO production.

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.

The invention discloses an andrographolide derivative nitric oxide donor compound as well as a preparation method and an application thereof. The derivative has a structure expressed by a formula (I), wherein R1 refers to hydrogen, organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, R2 refers to hydrogen, organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, R3 refers to hydrogen, organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, and at least one of R1, R2 and R3 is a functional group capable of releasing nitric oxide or an organic acid radical substituted by nitroxide group. The andrographolide derivative nitric oxide donor compound can be used for preparing medicaments for treating diabetes, medicaments for treating cardiovascular diseases, antimicrobial medicaments and antiviral medicaments. The medicaments can be prepared to tablets, capsules, granules, fine granules, powder, pills, patches, oral liquid or injection.

The invention provides a nitric oxide-donating glucocorticoid, which is a compound (II) or the ester or the slat thereof of the following general formula: A-L-X, wherein, A is steroid hormones residue, a bridge group L can be linked with the hydroxyl group on R' th or 17th in a form of ester linkage, a bivalent bridge group L is selected from -(CO)Ob1 (C R'4R'5) na (CO)(R7)-, wherein, na is an integer from 0 to 4, b1 is an integer from 0 to 1, R4, R' 4or R'5 and R5 are equal or mutually different and are selected from H which has the saturated or unsaturated alkyl with 1-8 carbon atoms; the chain can be a straight chain, a branched chain or a ring, and the preference is that na is equal to 2, b1is 0, R4 is equal to R5 is equal to R' 4 is equal to R' 5 is equal to H. The invention further provides the application of the compound, or the physiologically acceptable slat, or the solvate thereof in producing the medicines for treating inflammatory, allergic or anaphylactic diseases.

The present invention relates to a solid composition comprising a substance that improves the availability of nitric oxide, such as a nitric oxide donor or a biosynthetic nitric oxide precursor thereof or a direct or indirect nitric oxide potentiating agent, wherein arginine is the preferred compound, and combined with dithiolane, wherein the dithiolane and α-lipoic acid are the preferred compound, and this composition can be used to improve sexual function. The composition according to the invention comprises a nitric oxide donor or a precursor thereof in excess, based on the molar amount of the constituents. This composition is also suitable for improving sexual function. In particular, the present invention relates to the use of dithiolane in combination with nitric oxide donors or their precursors as a pharmaceutical treatment for sexual dysfunction.

The invention discloses a preparation method and application of a polycarbonate drug-loaded nano chemosensitizer based on nitric oxide. The sensitizer is prepared by self-assembling a polycarbonate block copolymer containing a nitric oxide donor and a small molecule chemotherapeutic drug. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide has the advantages of good water solubility, small toxic and side effects, good stability in a normal physiological environment and the like, and effectively solves the problems of poor water solubility, large toxic and side effects and the like of indissolvable chemotherapeutic drugs such as adriamycin, mitoxantrone and the like in clinical use. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide also has the features that the drug-loading capacity is high, the tumor targeting property is remarkable, the tumor microenvironment can be regulated and controlled, the ideal chemotherapy sensitization effect is achieved, and tumor recurrence is reduced.